EXPERT PERSPECTIVE VIRTUAL TUMOR BOARD
Tian Zhang, MD:Our third case is a 53-year-old man who went to his primary care provider for a gross hematuria that had persisted for a week after Bactrim treatment. Cystoscopy showed a 2.8 cm bladder mass. And on transurethral resection of the bladder, tumor pathology showed a high-grade invasive urothelial cancer with invasion into the muscularis propria. His imaging studies were positive for metastatic urothelial carcinoma in the retroperitoneal lymph nodes.
He went on to receive 6 cycles of cisplatin and gemcitabine, and then achieved a partial response from his initial chemotherapy. However, after about 8 months his surveillance CT [computed tomography] scan showed disease progression, including 1 new liver lesion. And his molecular testing results we are lucky to have back. His PD-L1 [programmed death-ligand 1] IHC [immunohistochemistry] was at 0%, but hisFGFR3was positive for a mutation at S249C, and that was done by a RT-PCR [reverse transcription polymerase chain reaction] assay.
His ECOG [Eastern Cooperative Oncology Group] performance status is excellent, it’s at 1; and his estimated glomerular filtration rate is 56; he also has adequate s hematologic and hepatic parameters.
Transcript edited for clarity.
FDA Accepts IND for UGN-103 in Low-Grade Intermediate-Risk NMIBC
April 15th 2024An investigational new drug application for UGN-103 was accepted by the FDA. A phase 3 study to assess the safety and efficacy of the agent in low-grade intermediate-risk non-muscle invasive bladder cancer is anticipated.
Read More
Study Shows Desire for Bladder-Sparing Treatments in High-Risk NMIBC
April 2nd 2024In an interview with Targeted Oncology, Joseph M. Jacob, MD, discussed how bladder preservation is the top reason for refusal of radical cystectomy in the TAR-200 monotherapy cohort of the SunRISe-1 study.
Read More